Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 57 min ago
Peer-reviewedCC BY-NC-ND 4.0Annals of Translational Medicine

Doravirine/islatravir (DOR-ISL) as a new once-daily oral single-tablet regimen for human immunodeficiency virus (HIV) treatment: unmet need or paradox of choice?

  • Amit C Achhra1
  • Onyema E Ogbuagu1
  1. 1Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA
Read full textDOICite

Related

  1. Prevalence of neural tube defects and major external structural abnormalities by antiretroviral treatment regimen in Botswana in 2014–22: a birth outcomes surveillance study
    Rebecca Zash, Modiegi Diseko, Lewis B Holmes +11
    The Lancet Global HealthPeer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
  2. Laryngeal cryptococcosis with clinical failure to fluconazole in a patient with common variable immunodeficiency: A treatment dilemma
    Rija Binte Rehan Alvi, Ross M. Mayerhoff, Eloy E. Ordaya
    Medical Mycology Case ReportsPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ
  3. Baseline radiographic and microbiologic predictors of treatment outcomes in a shortened all-oral regimen for MDR/RR-TB
    Edmund Q. L. Shen, Stephane Mpinda, Llang Maama +12
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textInfectious diseaseCrossref
  4. Beyond monocular acuity: Resolving the amblyopia treatment paradox with mechanism-targeted outcomes and modern testing methods
    Ling Gong, Seung Hyun Min, Xiaoning Yu +4
    Advances in Ophthalmology Practice and ResearchPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthDOAJPMC
  5. Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV
    Jesse C. Nussbaum, Michelle M. Pham, Ryan Vargo +6
    Antimicrobial Agents and ChemotherapyPeer-reviewedCC BY 4.0Full textInfectious diseaseDOAJPMC

Cite

BibTeXRIS
BibTeX
@article{achhra2026doravirineislatravir,
  title = {{Doravirine/islatravir (DOR-ISL) as a new once-daily oral single-tablet regimen for human immunodeficiency virus (HIV) treatment: unmet need or paradox of choice?}},
  author = {Amit C Achhra and Onyema E Ogbuagu},
  journal = {Annals of Translational Medicine},
  year = {2026},
  month = sep,
  doi = {10.21037/atm-2026-0134},
  url = {https://doi.org/10.21037/atm-2026-0134},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Doravirine/islatravir (DOR-ISL) as a new once-daily oral single-tablet regimen for human immunodeficiency virus (HIV) treatment: unmet need or paradox of choice?
AU  - Amit C Achhra
AU  - Onyema E Ogbuagu
PY  - 2026
DA  - 2026/09/21
JO  - Annals of Translational Medicine
DO  - 10.21037/atm-2026-0134
UR  - https://doi.org/10.21037/atm-2026-0134
SN  - 2305-5839
SN  - 2305-5847
ER  -